Initial clinical findings suggest that GLP-1 receptor agonists could provide an effective therapeutic strategy in patients with AD and those at risk, however, there remains a lack of sufficient evidence in large clinical samples to draw any firm conclusions. Here, GLP1R is linked to Alzheimer disease.